REC Aktienübersicht
Recordati Industria Chimica e Farmaceutica S.p.A. ist zusammen mit seinen Tochtergesellschaften weltweit in der Forschung, Entwicklung, Herstellung und Vermarktung von Arzneimitteln tätig.
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 4/6 |
Recordati Industria Chimica e Farmaceutica S.p.A. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | €49.94 |
| 52-Wochen-Hoch | €53.40 |
| 52-Wochen-Tief | €43.04 |
| Beta | 0.40 |
| 11 Monat Veränderung | -3.22% |
| 3 Monate Veränderung | -0.32% |
| 1 Jahr Veränderung | 10.24% |
| 33 Jahre Veränderung | -1.81% |
| 5 Jahre Veränderung | 26.91% |
| Veränderung seit IPO | 3,743.90% |
Aktuelle Nachrichten und Updates
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 07
We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Recent updates
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 07We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30Aktionärsrenditen
| REC | IT Pharmaceuticals | IT Markt | |
|---|---|---|---|
| 7D | -1.8% | -2.7% | 0.5% |
| 1Y | 10.2% | 12.9% | 14.3% |
Rendite im Vergleich zur Industrie: REC unter dem Niveau der Branche Italian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 15.2% erzielte.
Rendite vs. Markt: REC hinter dem Markt Italian zurück, der im vergangenen Jahr eine Rendite von 14.7 erzielte.
Preisvolatilität
| REC volatility | |
|---|---|
| REC Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 6.5% |
| 10% least volatile stocks in IT Market | 2.5% |
Stabiler Aktienkurs: REC hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: RECDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1926 | 4,455 | Rob Koremans | www.recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A. ist zusammen mit seinen Tochtergesellschaften weltweit in der Forschung, Entwicklung, Herstellung und Vermarktung von Arzneimitteln tätig. Das Unternehmen ist in den Segmenten Specialty and Primary Care und Rare Diseases tätig. Die Produktpipeline des Unternehmens umfasst REC 0559, das sich in Phase II zur Behandlung der neurotrophen Keratitis befindet, REC 0545 zur Behandlung der akuten Dekompensation bei Ahornsirup-Urin-Erkrankungen, ISTURISA zur Behandlung des endogenen Cushing-Syndroms und CYSTADROPS zur Behandlung von Cystinablagerungen auf der Hornhaut bei Patienten mit Cystinose.
Recordati Industria Chimica e Farmaceutica S.p.A.'s Grundlagenzusammenfassung
| REC grundlegende Statistiken | |
|---|---|
| Marktanteil | €10.23b |
| Gewinn(TTM) | €387.01m |
| Umsatz(TTM) | €2.22b |
26.4x
Kurs-Gewinn-Verhältnis4.6x
Kurs-Umsatz-VerhältnisIst REC zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| REC Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | €2.22b |
| Kosten der Einnahmen | €672.69m |
| Bruttogewinn | €1.55b |
| Sonstige Ausgaben | €1.16b |
| Umsatz | €387.01m |
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
Nov 08, 2024
| Gewinn per Aktie (EPS) | 1.89 |
| Bruttomarge | 69.75% |
| Nettogewinnspanne | 17.40% |
| Schulden/Eigenkapital-Verhältnis | 91.1% |
Wie hat sich REC auf lange Sicht entwickelt?
Historische Performance und Vergleiche